Develops targeted phospholipid drug conjugates for the treatment of cancer.
Cellectar Biosciences, Inc., a leading clinical biopharmaceutical company headquartered in Florham Park, New Jersey, is dedicated to advancing the discovery, development, and commercialization of innovative cancer treatments. The company's primary focus is on its lead product candidate CLR 131 (iopofosine I-131), a phospholipid drug conjugate (PDC). CLR 131 is currently undergoing Phase 2 clinical trials for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies, as well as Phase 2B trials for r/r multiple myeloma (MM) and Phase I studies for various pediatric cancers, r/r head and neck cancers, and additional r/r MM indications.
Cellectar Biosciences is also advancing CLR 1900, a PDC chemotherapeutic program in preclinical development aimed at treating solid tumors. The company collaborates on PDC programs with strategic partners such as Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, and collaborations with IntoCell Inc. and LegoChemBio to further expand its innovative pipeline.
Founded in 2002, Cellectar Biosciences continues to drive forward with a mission to address significant unmet medical needs in oncology. Through its robust research and development efforts and strategic partnerships, Cellectar Biosciences is poised to make meaningful advancements in cancer therapy, leveraging its specialized expertise in PDC technology to potentially transform treatment outcomes for cancer patients worldwide.